[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353632-105":59,"doc-detail-353632-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cyclic-di-gmp-suppresses-cancer-metastasis-by-targeting-proteasome-26s-subunit-non-atpase-3-independently-of-sting","Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING","","Cancer metastasis is a leading driver of cancer mortality, yet effective therapies remain limited. This study shows that the bacterial second messenger cyclic di-GMP potently suppresses metastasis, especially in metastatic breast cancer, in both cell and animal models with minimal toxicity. The mechanism involves inhibition of the NF-κB signaling pathway independent of STING. c-di-GMP directly binds PSMD3, a TBK1-binding activator, disrupting PSMD3–TBK1 interaction to modulate TBK1 phosphorylation and activate a noncanonical PSMD3 role. PSMD3 is highly expressed in malignant and metastatic breast cancers, particularly triple-negative disease, supporting PSMD3 as a therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cyclic-di-gmp-suppresses-cancer-metastasis-by-targeting-proteasome-26s-subunit-non-atpase-3-independently-of-sting/353632/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cyclic-di-gmp-suppresses-cancer-metastasis-by-targeting-proteasome-26s-subunit-non-atpase-3-independently-of-sting/353632.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does cyclic di-GMP affect cancer metastasis?","Question",{"text":112,"@type":113},"Cyclic di-GMP suppresses cancer metastasis in vitro and in vivo, particularly in metastatic breast cancer, while showing little toxicity in mice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does cyclic di-GMP work through STING?",{"text":117,"@type":113},"No. The antimetastatic effect occurs independently of STING, despite c-di-GMP previously being linked to STING as a sensor.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular mechanism links c-di-GMP to NF-κB?",{"text":121,"@type":113},"c-di-GMP inhibits NF-κB activity by directly binding PSMD3 and disrupting the PSMD3–TBK1 interaction, which alters TBK1 phosphorylation and activates a noncanonical PSMD3 function.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353632,1790420727,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nARTICLE OPEN  \nCyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING  \nJieqiong Wang 1,2, Alexander Mrozek1,2, Kewen Hu3,4, Hanyu You1,2, Sarah E. Traverse1,2, Hyemin Lee1,2, Shelya X. Zeng1,2, Xiufeng Pang 3, Heewon Park1,2 and Hua Lu1,2 ✉  \n\n|  | Cancer metastasis is the primary cause of cancer-related mortality, yet effective treatments remain limited. There is an urgent need to develop novel therapeutic strategies to combat metastasis. In this study, we demonstrate that the bacterial intracellular signaling molecule cyclic di-GMP (c-di-GMP, or cdG) exerts a potent inhibitory effect on cancer metastasis, particularly in metastatic breast cancer, via both in vitro and in vivo models, with little toxicity to mice. Interestingly, this antimetastatic function is achieved by suppressing the NF-κB signaling pathway, which is important for cancer progression and metastasis, but independent of STING, a previously identiﬁed c-di-GMP sensor and NF-κB regulator in mammalian cells. Surprisingly, c-di-GMP inhibits NF-κB activity (p-p65) by directly binding to the proteasome 26S subunit non-ATPase 3 (PSMD3) that we identiﬁed as a new TBK1-binding activator, and disrupting the interaction between PSMD3 and TBK1 . This PSMD3-TBK1 interaction boosts the phosphorylation and activation of TBK1, representing a noncanonical function of PSMD3 distinct from its established role in proteasomal degradation. Signiﬁcantly, PSMD3 is highly expressed in malignant and metastatic breast cancers, particularly triple-negative breast cancer. The compelling evidence strongly suggests PSMD3 as a promising target for developing a therapy against metastatic breast cancer. These ﬁndings underscore the high potential of c-di-GMP as a safe and effective therapeutic agent for metastatic cancers by targeting the PSMD3- |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| TBK1-NF-κB pathway. |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:44 ; [https://doi.org/10.1038/s41392-025-02553-9](https://doi.org/10.1038/s41392-025-02553-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nMetastasis, a deﬁning hallmark of cancer, is a highly complex and multistep process through which malignant cancer cells detach from the primary tumor, invade surrounding and distant tissues, and ultimately establish secondary tumors at remote organs.1,2 The development of metastatic disease is closely associated with poor clinical outcomes and remains the primary cause of cancerrelated mortality worldwide.3 Among various cancer types, breast cancer is a major contributor to metastatic burden, with triplenegative breast cancer (TNBC), poses a signiﬁcant clinical challenge because of its aggressive nature and high recurrence rates. TNBC is characterized by high invasiveness, early relapse, and a strong propensity to metastasize to vital organs, includingthe lung, liver, bone, and brain.4,5 Unlike hormone receptorpositive or HER2-positive breast cancer subtypes, TNBC lacks welldeﬁned molecular targets, severely limiting the availability of effective targeted therapies. Current treatment options largely rely on chemotherapy, which provides limited effects and is frequently accompanied by drug resistance and cancer recurrence.5 Given these clinical challenges, identifying novel molecular drivers of metastasis and developing targeted therapeutic strategies are urgently needed to effectively suppress metastatic progression and improve outcomes for patients with advanced breast cancer.  \nMetastasis relies on a subset of highly aggressive cancer cells that acquire the ability to adapt to dynamic microenvironments, survive detachment and circulation, and successfully colonize in distant org","cbCaibanrozOt7g4","https://ap.wps.com/l/cbCaibanrozOt7g4","pdf",8537213,17,"English","# Introduction\n## Metastasis and clinical challenges\n## Role of STING and c-di-GMP in immune signaling\n## Study rationale and target selection","[{\"question\":\"How does cyclic di-GMP affect cancer metastasis?\",\"answer\":\"Cyclic di-GMP suppresses cancer metastasis in vitro and in vivo, particularly in metastatic breast cancer, while showing little toxicity in mice.\"},{\"question\":\"Does cyclic di-GMP work through STING?\",\"answer\":\"No. The antimetastatic effect occurs independently of STING, despite c-di-GMP previously being linked to STING as a sensor.\"},{\"question\":\"What molecular mechanism links c-di-GMP to NF-κB?\",\"answer\":\"c-di-GMP inhibits NF-κB activity by directly binding PSMD3 and disrupting the PSMD3–TBK1 interaction, which alters TBK1 phosphorylation and activates a noncanonical PSMD3 function.\"}]","Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING | PDF",1790106467,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/248be8409d4b26bf12be104747577cb0.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ea97ae392603969de0cfb4b22e3baa8.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07072b78cc8622c1eb2008e9c711e997.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19e3f9988e891b01d4bcf1ca1dc53066.webp",980,1301]